Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.

Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ; South Australian Oesophageal Research Group.

Br J Surg. 2010 Jun;97(6):853-61. doi: 10.1002/bjs.7000.

PMID:
20301167
2.

MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus.

Dijckmeester WA, Wijnhoven BP, Watson DI, Leong MP, Michael MZ, Mayne GC, Bright T, Astill D, Hussey DJ.

J Gastrointest Surg. 2009 May;13(5):846-53. doi: 10.1007/s11605-009-0799-5. Epub 2009 Feb 4.

PMID:
19190970
3.

Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.

Barclay JY, Morris A, Nwokolo CU.

Eur J Gastroenterol Hepatol. 2005 Feb;17(2):221-7.

PMID:
15674101
4.

Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.

Soldes OS, Kuick RD, Thompson IA 2nd, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG.

Br J Cancer. 1999 Feb;79(3-4):595-603.

5.

Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.

Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR.

Surgery. 2005 Nov;138(5):924-31.

PMID:
16291394
6.

MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.

Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E.

Cancer Prev Res (Phila). 2013 Mar;6(3):196-205. doi: 10.1158/1940-6207.CAPR-12-0276.

7.

Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.

Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM, Salonga D, Groshen S, Tsao-Wei DD, DeMeester TR, Hölscher AH, Danenberg PV.

J Surg Res. 2001 Aug;99(2):301-6.

PMID:
11469901
8.

MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R.

Am J Pathol. 2009 May;174(5):1940-8. doi: 10.2353/ajpath.2009.080718. Epub 2009 Mar 26.

9.

The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.

Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM.

Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7.

10.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
11.

Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV.

J Gastrointest Surg. 2000 Mar-Apr;4(2):135-42.

PMID:
10675236
12.

Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma.

Wu GD, Beer DG, Moore JH, Orringer MB, Appelman HD, Traber PG.

Gastroenterology. 1993 Sep;105(3):837-44.

PMID:
8359653
13.

MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.

Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X.

Clin Cancer Res. 2009 Sep 15;15(18):5744-52. doi: 10.1158/1078-0432.CCR-09-0385. Epub 2009 Sep 8.

14.

Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.

Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN.

Cancer Res. 2005 Apr 15;65(8):3146-54.

15.
16.

Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus.

Vallböhmer D, DeMeester SR, Peters JH, Oh DS, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, DeMeester TR, Chandrasoma PT.

Dis Esophagus. 2006;19(4):260-6.

PMID:
16866857
17.

Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.

Vallböhmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, Demeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, DeMeester TR, Danenberg P.

Surgery. 2005 Oct;138(4):701-6; discussion 706-7.

PMID:
16269299
18.

Role of retinoid X receptor mRNA expression in Barrett's esophagus.

Brabender J, Lord RV, Metzger R, Park J, Salonga D, Danenberg KD, Hölscher AH, Danenberg PV, Schneider PM.

J Gastrointest Surg. 2004 May-Jun;8(4):413-22.

PMID:
15120365
19.

A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.

Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Hölscher AH, Yin J, Meltzer SJ, Danenberg KD, Danenberg PV, Lord RV.

Oncogene. 2004 Jun 10;23(27):4780-8.

PMID:
15107828
20.

Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.

Morita S, Matsumoto Y, Okuyama S, Ono K, Kitamura Y, Tomori A, Oyama T, Amano Y, Kinoshita Y, Chiba T, Marusawa H.

Carcinogenesis. 2011 Nov;32(11):1706-12. doi: 10.1093/carcin/bgr194. Epub 2011 Sep 1.

Items per page

Supplemental Content

Write to the Help Desk